Cargando…
Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholde...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462958/ https://www.ncbi.nlm.nih.gov/pubmed/37640462 http://dx.doi.org/10.1136/bmjopen-2023-072309 |
_version_ | 1785098147206266880 |
---|---|
author | Hogervorst, Milou A Møllebæk, Mathias Vreman, Rick A Lu, Ting-An Wang, Junfeng De Bruin, Marie Louise Leufkens, Hubert G M Mantel-Teeuwisse, Aukje Goettsch, Wim |
author_facet | Hogervorst, Milou A Møllebæk, Mathias Vreman, Rick A Lu, Ting-An Wang, Junfeng De Bruin, Marie Louise Leufkens, Hubert G M Mantel-Teeuwisse, Aukje Goettsch, Wim |
author_sort | Hogervorst, Milou A |
collection | PubMed |
description | OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholders may be achieved, and second, to determine to what extent convergence can be achieved. DESIGN: Qualitative study using eight online dual-moderator focus groups. SETTING: Discussions had a European focus and were contextualised in four case studies on head and neck cancer, diabetes mellitus, multiple sclerosis and myelodysplastic syndromes. PARTICIPANTS: Forty-two experienced (over 10 years) European regulators, HTA representatives and clinicians participated in the discussion. INTERVENTIONS: Participants received information on the case study and research topic in advance. An introductory background presentation and interview guide for the moderators were used to steer the discussion. RESULTS: Convergence may be achieved through improved communication institutionalised in multistakeholder early dialogues, shared definitions and shared methods. Required data sets should be inclusive rather than aligned. Deliberation and decision-making should remain independent. Alignment could be sought for pragmatic clinical trial designs and patient registries. Smaller and lower-income countries should be included in these efforts. CONCLUSION: Actors in the field expressed that improving synergy among stakeholders always involves trade-offs. A balance needs to be found between the convergence of processes and the institutional remits or geographical independence. A similar tension exists between the involvement of more actors, for example, patients or additional countries, and the level of collaboration that may be achieved. Communication is key to establishing this balance. |
format | Online Article Text |
id | pubmed-10462958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-104629582023-08-30 Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts Hogervorst, Milou A Møllebæk, Mathias Vreman, Rick A Lu, Ting-An Wang, Junfeng De Bruin, Marie Louise Leufkens, Hubert G M Mantel-Teeuwisse, Aukje Goettsch, Wim BMJ Open Health Policy OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholders may be achieved, and second, to determine to what extent convergence can be achieved. DESIGN: Qualitative study using eight online dual-moderator focus groups. SETTING: Discussions had a European focus and were contextualised in four case studies on head and neck cancer, diabetes mellitus, multiple sclerosis and myelodysplastic syndromes. PARTICIPANTS: Forty-two experienced (over 10 years) European regulators, HTA representatives and clinicians participated in the discussion. INTERVENTIONS: Participants received information on the case study and research topic in advance. An introductory background presentation and interview guide for the moderators were used to steer the discussion. RESULTS: Convergence may be achieved through improved communication institutionalised in multistakeholder early dialogues, shared definitions and shared methods. Required data sets should be inclusive rather than aligned. Deliberation and decision-making should remain independent. Alignment could be sought for pragmatic clinical trial designs and patient registries. Smaller and lower-income countries should be included in these efforts. CONCLUSION: Actors in the field expressed that improving synergy among stakeholders always involves trade-offs. A balance needs to be found between the convergence of processes and the institutional remits or geographical independence. A similar tension exists between the involvement of more actors, for example, patients or additional countries, and the level of collaboration that may be achieved. Communication is key to establishing this balance. BMJ Publishing Group 2023-08-28 /pmc/articles/PMC10462958/ /pubmed/37640462 http://dx.doi.org/10.1136/bmjopen-2023-072309 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Health Policy Hogervorst, Milou A Møllebæk, Mathias Vreman, Rick A Lu, Ting-An Wang, Junfeng De Bruin, Marie Louise Leufkens, Hubert G M Mantel-Teeuwisse, Aukje Goettsch, Wim Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title | Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title_full | Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title_fullStr | Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title_full_unstemmed | Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title_short | Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts |
title_sort | perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with european experts |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462958/ https://www.ncbi.nlm.nih.gov/pubmed/37640462 http://dx.doi.org/10.1136/bmjopen-2023-072309 |
work_keys_str_mv | AT hogervorstmiloua perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT møllebækmathias perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT vremanricka perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT lutingan perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT wangjunfeng perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT debruinmarielouise perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT leufkenshubertgm perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT mantelteeuwisseaukje perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts AT goettschwim perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts |